Evonile Pharma reports first results after change of control
By ScoutQuest · · 1 min read
- Timeline
- Within two months of the change in control
- Business model transition
- single-customer business model to marketing its brands with its own distribution network
- H2 FY27 priorities
- complete the organisational build-out, establish an appropriate cost structure and bring together a strong team
- Release
- Results press release
- Period
- Q2 FY27
📌 Within two months of the change in control, Evonile Pharma moved from a single-customer business model to marketing its brands with its own distribution network, field force and operating systems.
🎯 Management says its H2 FY27 priorities are to complete the organisational build-out, establish an appropriate cost structure and bring together a strong team.
Also from Evonile Pharma
Evonile Pharma Q2 and H1 FY27 results update: Q2 revenue down 38% YoY after business-model change
3 Nov 2026
Board approves unaudited results for September 2026 quarter; auditors' limited review unmodified
3 Nov 2026
BSE in-principle approval received for proposed rights issue of up to ₹9,000.00 million
1 Nov 2026
More numbers
- Revenue from operations, Q2 FY27₹56.1 crore
- Revenue from operations, H1 FY27₹159.9 crore
- ChrysCapital stake in Evonile Pharma70.68%
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.